Pharmacyclics, Inc.  

(Public, NASDAQ:PCYC)   Watch this stock  
Find more results for PCYC
254.75
+0.24 (0.09%)
May 4 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 254.73 - 256.05
52 week 82.51 - 260.47
Open 255.79
Vol / Avg. 0.00/936,319.00
Mkt cap 19.54B
P/E 236.68
Div/yield     -
EPS 1.08
Shares 76.79M
Beta 0.67
Inst. own 77%
Jul 29, 2015
Q2 2015 Pharmacyclics Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
May 1, 2015
Q1 2015 Pharmacyclics Inc Earnings Release
Mar 5, 2015
AbbVie to Acquire Pharmacyclics Conference Call - Webcast
Mar 4, 2015
Pharmacyclics Inc at Cowen Health Care Conference
Feb 18, 2015
Q4 2014 Pharmacyclics Inc Earnings Call
Feb 18, 2015
Q4 2014 Pharmacyclics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin 21.88% 11.80%
Operating margin 32.04% 16.77%
EBITD margin - 48.35%
Return on average assets 25.89% 9.42%
Return on average equity 32.85% 11.82%
Employees 607 -
CDP Score - -

Address

995 E ARQUES AVE
SUNNYVALE, CA 94085-4521
United States - Map
+1-408-7740330 (Phone)
+1-408-7740340 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Pharmacyclics, Inc. is a United States-based biopharmaceutical company engaged in developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases. The Company designs, develops and commercializes therapies intended to improve quality of life, increase duration of life and resolve unmet medical healthcare needs of the patients. The Company also identifies and controls product candidates based on scientific development and administrational expertise. On November 13, 2013, the United States Food and Drug Administration approved IMBRUVICATM under accelerated approval as a monotherapy for the treatment of patients with mantle cell lymphoma (MCL). On November 13, 2013, the Company launched, developed, and commercialized its first product, IMBRUVICATM in the United States. In addition to IMBRUVICATM, the Company has three other product candidates in clinical development and other preclinical molecules in lead optimization.

Officers and directors

Robert W. Duggan Chairman of the Board, Chief Executive Officer
Age: 70
Bio & Compensation  - Reuters
Manmeet Soni Chief Financial Officer, Executive Vice President - Finance, Chief Accounting Officer, Treasurer
Age: 37
Bio & Compensation  - Reuters
Mahkam Zanganeh DDS Chief Operating Officer
Age: 44
Bio & Compensation  - Reuters
Shawn Cline Tomasello Chief Commercial Officer
Bio & Compensation  - Reuters
Heow Tan Chief of Technical Operations
Age: 56
Bio & Compensation  - Reuters
Robert F. Booth Ph.D. Independent Director
Age: 61
Bio & Compensation  - Reuters
Kenneth A. Clark Independent Director
Age: 56
Bio & Compensation  - Reuters
Eric H. Halvorson Independent Director
Age: 65
Bio & Compensation  - Reuters
Minesh P. Mehta M.D. Independent Director
Age: 57
Bio & Compensation  - Reuters
David Duane Smith Ph.D. Independent Director
Age: 44
Bio & Compensation  - Reuters